# Transplanted Pig Kidney Survives Record 271 Days in Human Recipient
A Massachusetts man has achieved a medical milestone by surviving with a genetically modified pig kidney for nine months, marking the longest documented function of a xenotransplant organ in a living recipient. The kidney operated in his body for 271 days before the transplant ultimately failed, demonstrating substantial progress in solving one of medicine's most persistent challenges: the severe shortage of human organs for transplantation.
The recipient, whose case is being studied as part of an ongoing FDA-regulated clinical trial, received the pig kidney in a groundbreaking surgical procedure that represents years of research into xenotransplantation, the process of transplanting organs from one species to another. The kidney came from a pig that had undergone 10 genetic modifications to prevent rejection and ensure proper function in a human body. Scientists at the University of Maryland Medical Center and their collaborators engineered the pig to remove problematic genes while inserting human genes that would allow the organ to be recognized as "self" by the recipient's immune system.
The extended survival period exceeds previous xenotransplant records significantly. Prior pig kidney transplants in humans lasted weeks or months at best, making this 271-day survival a watershed moment for regenerative medicine. The breakthrough builds directly on earlier successes from 2023, when the same research team at University of Maryland first implanted a pig kidney into a living patient.
Roughly 90,000 people in the United States currently wait for kidney transplants, and thousands die annually while on dialysis awaiting a suitable human donor organ. The shortage has only intensified as demand outpaces supply. Xenotransplantation research offers a potential solution to this organ crisis by providing a renewable source of transplantable organs. Pigs are particularly useful candidates because their organs are roughly similar in size to human organs, their breeding is well-controlled, and the procedure can theoretically be repeated as needed.
The pig kidney eventually required removal when the transplant failed, likely due to rejection despite the genetic modifications and immunosuppressive medications the patient took. Understanding why rejection ultimately occurred remains a focus for researchers working to improve future xenotransplants. The team will analyze the kidney to identify the specific mechanisms that led to failure, potentially revealing adjustments needed for longer survival periods.
The research involves collaboration between multiple institutions and is being conducted under careful FDA oversight given the experimental nature of the procedure. Participants in such trials undergo rigorous monitoring and must accept substantial risks in exchange for the possibility of extended life and improved quality compared to dialysis. The recipient in this case was able to resume many normal activities during the nine-month period with the functioning kidney, demonstrating that xenotransplants can provide genuine quality-of-life benefits beyond mere survival.
This achievement reflects decades of incremental progress in immunology, genetic engineering, and surgical technique. Scientists continue refining the genetic modifications, adjusting immunosuppressive drug regimens, and developing better monitoring methods to extend survival times further. The goal remains clear: eventually develop xenotransplantation as a reliable, scalable solution to organ shortage that could save thousands of lives annually.